Vitality Biopharma Advisor To Present At 11th National Clinical Conference On Cannabis Therapeutics

LOS ANGELES, CA--(Marketwired - May 17, 2017) - Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality Biopharma,” “Vitality”, or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, is pleased to announce the appointment of Dr. Caroline MacCallum MD, FRPC (Internal Medicine), BSc Pharm to its clinical advisory board.

Dr. MacCallum is a member of the faculty of the 11th National Clinical Conference on Cannabis Therapeutics being held in Berkeley, California May 17-20, and is presenting a talk on “Cannabis for Central Sensitivity Syndrome.” The event is sponsored by Patients out of Time a 501(c)(3) non-profit educational charity dedicated to educating healthcare professionals, organizations, and the general public about the therapeutic use of cannabis and the endocannabinoid system.

Currently, she is a clinical instructor in the Department of Medicine at the University of British Columbia (UBC) where she provides inpatient care on the Internal Medicine Ward at the UBC Hospital and Bone Marrow Transplant Ward. She is also a guest lecturer and preceptor for UBC Faculty of Pharmaceutical Sciences Pharm D Program, and the Medical director at Greenleaf Medical Clinic, a cannabis clinic in Langley, British Columbia that assesses patients’ suitability for therapy with legal, Health Canada approved medical cannabis. Dr. MacCallum’s research interests include the multimodal effects of cannabis on symptom clusters and central sensitivity syndrome, and use of cannabis for reducing polypharmacy and opioid use.

Robert Brooke, CEO of Vitality Biopharma states, “Dr. MacCallum brings a wealth of insight from her clinical experience that can guide our development of cannabinoid therapeutics. We are excited to work with her to advance our shared research interests, especially in demonstrating the ability of cannabinoids to be used as an alternative to opioid pain medications.”

About Vitality Biopharma (OTCQB: VBIO)
Vitality Biopharma is dedicated to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. For more information, visit: www.vitality.bio. Follow us on Facebook, Twitter and LinkedIn.

Notice Regarding Forward-Looking Statements
This news release contains “forward-looking statements” as that term is defined in Section 27(a) of the United States Securities Act of 1933, as amended and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.